Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
10.52
-0.59 (-5.31%)
At close: Mar 6, 2026, 4:00 PM EST
10.51
-0.01 (-0.10%)
After-hours: Mar 6, 2026, 4:32 PM EST
Valneva SE Revenue
Valneva SE had revenue of 29.41M EUR in the quarter ending September 30, 2025, a decrease of -35.82%. This brings the company's revenue in the last twelve months to 179.91M, up 13.48% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
179.91M EUR
Revenue Growth
+13.48%
P/S Ratio
4.47
Revenue / Employee
257,017 EUR
Employees
700
Market Cap
943.91M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | 113.04M | 7.74M | 7.35% |
| Dec 31, 2017 | 105.29M | 7.40M | 7.56% |
| Dec 31, 2016 | 97.89M | 14.56M | 17.47% |
| Dec 31, 2015 | 83.33M | 40.91M | 96.41% |
| Dec 31, 2014 | 42.43M | 6.44M | 17.89% |
| Dec 31, 2013 | 35.99M | 326.00K | 0.91% |
| Dec 31, 2012 | 35.67M | 2.78M | 8.46% |
| Dec 31, 2011 | 32.88M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MannKind | 348.97M |
| Arvinas | 262.60M |
| Phathom Pharmaceuticals | 175.11M |
| ARS Pharmaceuticals | 142.77M |
| CytomX Therapeutics | 113.63M |
| Arbutus Biopharma | 14.61M |
| Janux Therapeutics | 10.00M |
| KalVista Pharmaceuticals | 1.43M |
VALN News
- 4 days ago - Valneva to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 15 days ago - Valneva sees lower 2026 sales as third-party revenue winds down - Seeking Alpha
- 15 days ago - Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook - Wallstreet:Online
- 15 days ago - Valneva Reports Preliminary Unaudited 2025 Revenue and Cash and Provides 2026 Outlook - GlobeNewsWire
- 21 days ago - Valneva Provides Update on Recommendations for Use of IXCHIQ in the United Kingdom - Wallstreet:Online
- 21 days ago - Valneva Provides Update on Recommendations for Use of IXCHIQ® in the United Kingdom - GlobeNewsWire
- 4 weeks ago - VALNEVA Declaration of shares and voting rights: January 31, 2026 - GlobeNewsWire
- 4 weeks ago - Valneva and Instituto Butantan Announce Initiation of a Pilot Vaccination Campaign in Brazil with Single-Shot Chikungunya Vaccine IXCHIQ - Wallstreet:Online